1. Cybin participates in H.C. Wainwright Investment Conference on Sept 8, 2025. 2. Company focuses on novel treatments for mental health issues. 3. CYB003 is in Phase 3 for depression; CYB004 in Phase 2 for anxiety. 4. Cybin received FDA Breakthrough Therapy Designation for CYB003.
The announcement of participation in a prestigious investment conference often leads to increased visibility and can positively influence investor sentiment. Previous instances show stocks often rally after participation in such events, as seen with other biotech firms gaining interest post-presentations.
The focus on innovative mental health treatments and conference participation signals potential growth. This aligns with market demand for effective therapies, indicating a likelihood of increased investor interest and potential price movement.
The conference provides immediate exposure that could lead to short-term stock price increases. Investors often react quickly to news from such high-visibility events, affecting stock movements shortly thereafter.
Cybin Inc. (NYSE:CYBN) (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options, today announced that George Tziras, Cybin's Chief Business Officer, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference on Monday, September 8, 2025, at 11:00 a.m. ET.
The webcast and replay will be available on the Company's investor relations website on the Events & Presentations page.
About Cybin
Cybin® is a late-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative next-generation treatment options to address the large unmet need for people who suffer from mental health conditions.
With promising class leading data, Cybin is working to change the mental health treatment landscape through the introduction of novel drugs that provide effective and durable results for patients. The Company is currently developing CYB003, a proprietary deuterated psilocin analog, in Phase 3 studies for the adjunctive treatment of major depressive disorder that has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration and CYB004, a proprietary deuterated N, N-dimethyltryptamine molecule in a Phase 2 study for generalized anxiety disorder. The Company also has a research pipeline of investigational, 5-HT-receptor focused compounds.
Founded in 2019, Cybin is operational in Canada, the United States, the United Kingdom and Ireland. For Company updates and to learn more about Cybin, visit www.cybin.com or follow the team on X, LinkedIn, YouTube and Instagram.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250904761339/en/
Investor Contact:
Candice Masse
astr partners
Managing Director
(978) 879-7273
candice.masse@astrpartners.com
Media Contact:
Gabriel Fahel
Chief Legal Officer
Cybin Inc.
1-866-292-4601
irteam@cybin.com – or – media@cybin.com